Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
Patient preferences, convenience, and bone turnover markers were evaluated for the monthly ibandronate over the weekly risedronate regimen in Korean postmenopausal osteoporotic women. This was a 6-month, prospective, randomized, open-label, multicenter study with a two-period and two-sequence crossover treatment design. After a 30-day screening period, eligible participants with postmenopausal osteoporosis were randomized to receive either monthly oral ibandronate 150 mg for 3 months followed by weekly oral risedronate 35 mg for 12 weeks (sequence A) or the same regimen in reverse order (sequence B). Patient preference and convenience were evaluated by questionnaire. The changes in serum C-telopeptide after 3 months of treatment were analyzed. A total of 365 patients were enrolled in this study (sequence A 182, sequence B 183). Of patients expressing a preference (83.4%), 74.8% preferred the monthly ibandronate regimen over the weekly regimen (25.2%). More women stated that the monthly ibandronate regimen was more convenient (84.2%) than the weekly regimen (15.8%). There was no significant difference in the change in bone turnover marker between the two treatments. The two regimens were similarly tolerable. There were fewer adverse events in the monthly ibandronate group compared to the weekly risedronate group in terms of gastrointestinal side effects (nausea and abdominal distension). This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens.
Chung
Yoon-Sok
YS
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
Lim
Sung-Kil
SK
Chung
Ho-Yeon
HY
Lee
In-Kyu
IK
Park
Il-Hyung
IH
Kim
Ghi-Su
GS
Min
Yong-Ki
YK
Kang
Moo-Il
MI
Chung
Dong-Jin
DJ
Kim
Yong-Ki
YK
Choi
Woong Hwan
WH
Shong
Min Ho
MH
Park
Ji-Hyun
JH
Byun
Dong-Won
DW
Yoon
Hyun-Koo
HK
Shin
Chan Soo
CS
Lee
Yil-Seob
YS
Kwon
Nam-Hee
NH
D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001842:Bone and Bones / Q000378:metabolism; D024042:Collagen Type I / Q000378:metabolism; D018592:Cross-Over Studies; D004164:Diphosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D007723:Korea; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D057240:Patient Preference; D010455:Peptides / Q000378:metabolism; D011446:Prospective Studies; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077557:Ibandronic Acid